Oxford Begins Trials For First Vaccine Targeting Rare Bundibugyo Ebola Virus
More Business & Finance news · Trending news
Published 5/23/2026, 12:21:14 AM · Updated 5/23/2026, 1:37:32 AMBy TheBriefWire Editorial Team
Key points
- Oxford Begins Trials For First Vaccine Targeting Rare Bundibugyo Ebola Virus Published By, Last Updated: May 23, 2026, 05:51 IST University of Oxford scientists begin trials of a viral vector vaccine targeting the rare Bundibugyo Ebola strain, aiming to close a major gap in global outbreak preparedness.
- Representational image.
- (Image: Shutterstock) Scientists at the University of Oxford are developing what could become the world’s first vaccine targeting the rare Bundibugyo strain of the Ebola virus, a variant responsible for severe outbreaks but for which no approved vaccine currently exists.
- Researchers have begun early-stage clinical trials to test the safety and immune response of the vaccine candidate, aimed at protecting against Bundibugyo ebolavirus — one of several species that cause Ebola virus disease.
- The project is being led by Oxford’s Pandemic Sciences Institute and the Oxford Vaccine Group, institutions that previously played key roles in developing the Oxford-AstraZeneca Covid-19 vaccine.
Published May 23, 2026.
Quick Summary
Oxford Begins Trials For First Vaccine Targeting Rare Bundibugyo Ebola Virus Published By, Last Updated: May 23, 2026, 05:51 IST University of Oxford scientists begin
Why It Matters
This development is important because it may impact public opinion, policy decisions, and future developments related to Oxford Begins Trials For First Vaccine Targeting Rare Bundib.
Key Takeaways
- Oxford Begins Trials For First Vaccine Targeting Rare Bundibugyo Ebola Virus Published By, Last Updated: May 23, 2026, 05:51 IST University of Oxford scientists begin trials of a viral vector vaccine targeting the rare Bundibugyo Ebola strain, aiming to close a major gap in global outbreak preparedness.
- Representational image.
- (Image: Shutterstock) Scientists at the University of Oxford are developing what could become the world’s first vaccine targeting the rare Bundibugyo strain of the Ebola virus, a variant responsible for severe outbreaks but for which no approved vaccine currently exists.
- Researchers have begun early-stage clinical trials to test the safety and immune response of the vaccine candidate, aimed at protecting against Bundibugyo ebolavirus — one of several species that cause Ebola virus disease.
- The project is being led by Oxford’s Pandemic Sciences Institute and the Oxford Vaccine Group, institutions that previously played key roles in developing the Oxford-AstraZeneca Covid-19 vaccine.
📌 Source: News18
The BriefWire